| A highly efficient human pluripotent stem cell microglia model displays a neuronal-co-culture-specific expression profile and inflammatory response W Haenseler, SN Sansom, J Buchrieser, SE Newey, CS Moore, ... Stem cell reports 8 (6), 1727-1742, 2017 | 480 | 2017 |
| CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells R Flynn, A Grundmann, P Renz, W Hänseler, WS James, SA Cowley, ... Experimental hematology 43 (10), 838-848. e3, 2015 | 162 | 2015 |
| Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson’s iPSC-derived dopamine neurons F Zambon, M Cherubini, HJR Fernandes, C Lang, BJ Ryan, V Volpato, ... Human Molecular Genetics 28 (12), 2001-2013, 2019 | 153 | 2019 |
| Excess α-synuclein compromises phagocytosis in iPSC-derived macrophages W Haenseler, F Zambon, H Lee, J Vowles, F Rinaldi, G Duggal, ... Scientific reports 7 (1), 9003, 2017 | 109 | 2017 |
| LRRK2 is recruited to phagosomes and co-recruits RAB8 and RAB10 in human pluripotent stem cell-derived macrophages H Lee, R Flynn, I Sharma, E Haberman, PJ Carling, FJ Nicholls, ... Stem Cell Reports 14 (5), 940-955, 2020 | 82 | 2020 |
| Concise review: modeling neurodegenerative diseases with human pluripotent stem cell-derived microglia W Haenseler, L Rajendran Stem Cells 37 (6), 724-730, 2019 | 49 | 2019 |
| Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy C Brendel, W Hänseler, V Wohlgensinger, M Bianchi, S Tokmak, ... Human gene therapy methods 24 (3), 151-159, 2013 | 27 | 2013 |
| Human induced pluripotent stem cell-derived vessels as dynamic atherosclerosis model on a chip A Mallone, C Gericke, V Hosseini, K Chahbi, W Haenseler, MY Emmert, ... | 8 | 2020 |
| Lentiviral gene therapy vector with UCOE stably restores function in iPSC-derived neutrophils of a CGD patient W Haenseler, E Kuzmenko, A Smalls-Mantey, C Browne, R Seger, ... Matters 2018, 2018 | 8 | 2018 |
| Systematic identification of structure-specific protein–protein interactions A Holfeld, D Schuster, F Sesterhenn, AK Gillingham, P Stalder, ... Molecular Systems Biology 20 (6), 651-675, 2024 | 6 | 2024 |
| An approach to characterize mechanisms of action of anti-amyloidogenic compounds in vitro and in situ P Stalder, T Serdiuk, D Ghosh, Y Fleischmann, L Malinovska, ... bioRxiv, 2023.12. 18.572111, 2023 | 1 | 2023 |
| Human induced pluripotent stem cell-derived arteries as personalized models of atherosclerosis on-a-chip A Mallone, C Gericke, V Hosseini, V Vogel, K Chahbi, JH Walther, ... bioRxiv, 2020 | 1 | 2020 |
| Treatment of chronic granulomatous disease WU Siler, J Reichenbach, W Hänseler US Patent App. 17/765,172, 2022 | | 2022 |
| S3‐02‐03: Modelling Microglia with Human Pluripotent Stem Cells SA Cowley, W Haenseler Alzheimer's & Dementia 12, P268-P268, 2016 | | 2016 |
| Lentiviral SIN-vector for p47phox-deficient Chronic Granulomatous Disease Gene Therapy R Valencia, D Wrona, C Brendel, W Haenseler, G Santilli, A Thrasher, ... HUMAN GENE THERAPY 26 (10), A61-A62, 2015 | | 2015 |
| CRISPR-mediated Genotypic and Phenotypic Correction of a Chronic Granulomatous Disease R Flynn, A Grundmann, P Renz, W Haenseler, WS James, SA Cowley, ... | | 2015 |
| Lentiviral vector for p47phox gene therapy W Haenseler, C Brendel, G Santili, W James, S Cowley, A Thrasher, ... | | 2013 |
| Prevention of silencing by UCOE deletion constructs W Haenseler, C Brendel, G Santili, W James, S Cowley, A Thrasher, ... | | 2012 |
| HUMAN MIR223 PROMOTER AS NOVEL MYELOSPECIFIC PROMOTER FOR CGD GENE THERAPY C Brendel, W Haenseler, V Wohlgensinger, M Bianchi, E Kouzmenco, ... JOURNAL OF CLINICAL IMMUNOLOGY 32, 133-133, 2012 | | 2012 |
| Development of a Silencing Resistant Myelospecific Next Generation Gene Therapy Vector for Gene Therapy of the P47phox-deficient Form of Chronic Granulomatous Disease W Hänseler | | 2012 |
sally cowleyHead, James Martin Stem Cell Facility, University of Oxford在 path.ox.ac.uk 的电子邮件经过验证
